Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow obstruction and airway inflammation. Although typically neutrophilic, COPD is eosinophil-predominant in 10%‒40% of cases.[@CIT0001]--[@CIT0003] Increased airway or blood eosinophil counts are associated with a good response to corticosteroids in stable COPD[@CIT0003] and during exacerbations.[@CIT0004] Interleukin-5 (IL-5) binds with high affinity to the IL-5 receptor (R) alpha (IL-5Rα) subunit and plays a pivotal role in the differentiation and maturation of eosinophils in the bone marrow and their survival in tissue.[@CIT0001] In a 1-year randomized placebo-controlled trial of benralizumab,[@CIT0005] a humanized, afucosylated, monoclonal antibody that inhibits IL-5Rα activation and promotes antibody-dependent cell-mediated cytotoxicity (leading to near complete eosinophil depletion), improvements in lung function and symptoms and reduction in exacerbations were observed in patients with eosinophilic inflammation. However, in non-eosinophilic COPD patients, exacerbation frequency increased following benralizumab treatment vs placebo. Likewise, in a 6-month trial, the IL-5 neutralizing monoclonal antibody mepolizumab[@CIT0006] reduced exacerbations vs placebo in COPD patients with an increased blood eosinophil count but resulted in a greater exacerbation frequency in those with a low blood eosinophil count. This finding contrasts with that for asthma for which absence of eosinophilic inflammation is associated with neither benefit nor harm to anti‒IL-5(R).[@CIT0001] Interestingly, the airway microbiome is distinct between COPD patients with vs those without eosinophilic inflammation.[@CIT0007] Corticosteroid therapy alters the airway microbiome[@CIT0007] and consequently might hinder recovery during exacerbations in patients without eosinophilic inflammation.[@CIT0004] Whether this exacerbation relationship to low eosinophil count is genuine and these effects are partly because of attenuation of eosinophilic inflammation remain unknown. We, therefore, hypothesized that reduction in eosinophilic airway inflammation following benralizumab treatment increases airway bacterial load.

Methods {#S0002}
=======

Sputum samples were collected from COPD patients participating in the Phase II trial[@CIT0005] of benralizumab at 28 days before baseline, at baseline, and 57 and 255 days after receiving benralizumab or placebo. Written informed consent was provided by all patients. The study was conducted in accordance with the Declaration of Helsinki and was approved by the national and local ethics committees ([Table S1](#ST0001)). Supernatants were stored at −80 °C. For those patients who provided adequate sputum supernatant (\>100 μL) and ≥1 sample before and after therapy, DNA was extracted using QIAamp DNA mini kit (QIAGEN, Hilden, Germany) as per the manufacturer's protocol. Hydrolysis-based TaqMan assays were used to quantify 16S rDNA gene load (Integrated DNA Technologies \[IDT\], Coralville, Iowa) and *Haemophilus influenzae, Moraxella catarrhalis*, and *Streptococcus pneumoniae* by targeting the *FucP, CopB* (Applied Biosystems Life Technologies), and *pneumolysin* (IDT) genes, respectively. Quantification was determined relative to prepared standard curves for each bacterial strain by using Stratagene Mx3000P (Stratagene; La Jolla, CA) ([Table S2](#ST0002)).

Ex-vivo peripheral blood eosinophils and neutrophils of \>95% purity from healthy individuals were isolated as previously described.[@CIT0008] In vitro,*Escherichia coli* (strain PA360), *H. influenzae* (NCTC11872), and *S. pneumoniae* (D39), grown to late-log phase, were incubated alone or with blood eosinophils or neutrophils in triplicate for 1 h at 37 °C in the presence of 0.1% (*E. coli, H. influenzae*) or 10% (*S. pneumoniae*) non-heat inactivated human serum. We chose serum concentrations that were sublethal for nontypeable *H. influenzae* and *E. coli* based on titration experiments. Colony forming units were enumerated for each condition to determine the bacterial killing effect of each granulocyte.

Statistical analysis was performed using R 3.4.1 (The R Foundation for Statistical Computing) and PRISM (GraphPad; La Jolla, CA). Change in bacterial load over time within the treatment or placebo group was performed by fitting a generalized linear mixed model for each of 16S rDNA, *H. influenzae*, and *S. pneumoniae*. The dependent variables were time, treatment group, and an interaction term, time\*treatment group. A random intercept and a random effect for time were included. Correlations were undertaken between change in bacterial load, forced expiratory volume in 1 s, and symptoms and health status. Comparisons were made between conditions for bacterial killing experiments by 2-way analysis of variance.

Results {#S0003}
=======

Sputum supernatant samples were assessed from 14 benralizumab-treated and 15 placebo-treated patients. Clinical characteristics were similar between the groups ([Table S3](#ST0003)). The 16S rDNA load decreased following benralizumab treatment but remained unchanged with placebo ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}). The quantity of *S. pneumoniae* in the benralizumab and placebo groups decreased significantly, with the reduction numerically and statistically greater in the benralizumab group ([Figure 1C](#F0001){ref-type="fig"} and [D](#F0001){ref-type="fig"}). The reduction in 16S rDNA load was associated with a reduction in the quantity of *S. pneumoniae* in the benralizumab group but not in the placebo group ([Figure 1C](#F0001){ref-type="fig"} and [D](#F0001){ref-type="fig"}). However, there were no significant changes in the quantity of *H. influenzae* ([Figure 1E](#F0001){ref-type="fig"} and [F](#F0001){ref-type="fig"}) or *M. catarrhalis* (data not shown) in the 2 treatment groups. The reduction in total bacterial load, or quantity of *S. pneumoniae* in the sputum supernatants in benralizumab-treated patients, was not associated with either baseline blood eosinophil count or change in lung function, symptoms or health status following treatment with benralizumab. In contrast with ex-vivo neutrophils, ex-vivo blood eosinophils did not kill *H. influenzae* or *S. pneumoniae* in vitro ([Figure 2A](#F0002){ref-type="fig"}‒[D](#F0002){ref-type="fig"}).Figure 1Sputum bacterial load in response to benralizumab vs placebo. Plots for (**A** and **B**) total bacterial load, (**C** and **D**) *Streptococcus pneumoniae*, and (**E** and **F**) *Haemophilus influenzae* for individual patients from Day −28 to Day 225 in response to benralizumab vs placebo. Vertical dotted lines delineate first treatment dose. Horizontal dotted lines represent patients with a baseline sputum eosinophil count ≥3%. *P*-values are provided for the mixed models, including all time points, but excluding Day −28.Figure 2Ex-vivo blood eosinophils do not kill *Haemophilus influenzae* or *Streptococcus pneumoniae* in vitro. *Escherichia coli* (**A**), *H. influenzae* (**B**), and *S. pneumoniae* (**C**) were incubated alone or with purified blood eosinophils or neutrophils, as indicated in triplicate (x-axis), for 1 h at 37 °C, with shaking at 200 rpm in U-bottom plates. Bacteria and cells were incubated in a ratio of \~1:100 in the presence of either 0.1% (**A** and **B**) or 10% (**C**) non-heat inactivated AB-human serum supplemented with RPMI. By removing 3×10 µL aliquots from each well and incubating overnight on agar, colony forming units were determined in each 10 µL suspension. Data in **A**, **B**, and **C** represent data from one individual. Data in **D** represents cumulative data from three separate healthy donors showing % change in CFU/10 µL for each bacterium tested in the presence of eosinophils or neutrophils relative to bacteria alone. **A**, **B**, and **C** bars indicate mean (SEM), with statistics calculated using a 2-way ANOVA (Dunnett's multiple comparison test).**Abbreviations:** ANOVA, analysis of variance; CFU, colony forming unit; rpm, revolutions per minute; RPMI, Roswell Park Memorial Institute medium; SEM, standard error of the mean.

Discussion {#S0004}
==========

Contrary to our hypothesis, we found that 16S rDNA load and the quantity of the common pathogen *S. pneumoniae* decreased following benralizumab treatment. However, this was not associated with clinical outcomes. There was also a small decrease in the quantity of *S. pneumoniae* in the placebo group. In vitro, blood eosinophils did not affect bacterial killing of *S. pneumoniae* and *H. influenzae*, while small effects were observed on *E. coli*, similar to previously published reports.[@CIT0009],[@CIT0010] Therefore, the effects observed in vivo are more likely an indirect effect of benralizumab attenuating eosinophilic inflammation. Macrophage efferocytosis of eosinophils[@CIT0008] might further impair macrophage phagocytosis of bacteria; therefore, their reduction may improve bacterial clearance. Similarly, reduction in eosinophilic inflammation is likely to result in a greater percentage of neutrophils that might consequently enhance bacterial clearance. Intriguingly, although these possible mechanisms might explain the reduction in bacterial load following benralizumab treatment, they do not provide a rationale for the apparent increased exacerbation risk in non-eosinophilic COPD patients, as observed in the Phase IIa study, following anti‒IL-5Rα treatment. Further investigation is needed to assess whether the clinical findings are real and what the underlying cause may be.

The retrospective study design limited the number of available samples, restricted analysis to sputum supernatants rather than whole sputum plugs, and limited us to targeted quantitative polymerase chain reactions rather than broader sequencing approaches. Future prospective studies, including whole sputum and microbiome sequencing, are required to further determine the effects of anti‒IL-5/anti‒IL-5Rα therapies on airway ecology.

Conclusions {#S0005}
===========

Sputum 16S rDNA and *S. pneumoniae* bacterial load are reduced in COPD patients following benralizumab treatment. However, how biologics affect the airway microbiome in obstructive lung diseases warrants further investigation.
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Abbreviation list {#S0006}
=================

COPD, chronic obstructive pulmonary disease; IDT, Integrated DNA Technologies; IL-5, interleukin-5; IL-5Rα, IL-5 receptor alpha; R, receptor.
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Table S1List of institutional review boards/independent ethics committeesSite numberInvestigator nameName and address of IRB/IEC1178101Robert CowieOffice of Medical Bioethics,\
Heritage Medical Research Clinic,\
3300 Hospital Dr. NW,\
Calgary, Canada1211701Francois MaltaisL'Institut de cardiologie et de pneumologie deQuebec, 2725 Chemin Ste-Foy, Quebec, Canada1224301Kieran KillianHamilton Health Sciences, 293 Wellington St. N, Hamilton, Canada1286101Andre FrechetteCentre de Recherche Inc., 205 Montmagny St, Quebec, Canada1254401Darcy MarciniukRoyal University Hospital, l103 Hospital Drive, Saskatoon, Canada1207401Guy Chouinard372 Hollandview Trail, Suite 300, Aurora, Ontario, Canada1214701Ingrid TitlestadDen Videnskabsetiske Komite for Region, Syddanmark, Regionshuset Damhaven 12, Vejle, Denmark1214801Vibeke BackerDen Videnskabsetiske Komite for Region, Syddanmark, Regionshuset Damhaven 12, Vejle, Denmark1214901Ronald DahlDen Videnskabsetiske Komite for Region, Syddanmark, Regionshuset Damhaven 12, Vejle, Denmark1227001Niels SeersholmDen Videnskabsetiske Komite for Region, Syddanmark, Regionshuset Damhaven 12, Vejle, Denmark1286301Jesper SonneDen Videnskabsetiske Komite for Region, Syddanmark, Regionshuset Damhaven 12, Vejle, Denmark1086301Roland BuhlAntrag (AMG/multi) - 837.364.10(7373), Landesärztekammer Rheinland-Pfalz EC, Deutschhausplatz 3, Mainz, Germany1285801Oliver KornmannEthikkommission (EC) der\
Landesärztekammer Hessen, Im Vogelsgesang 3, Frankfurt, Germany1077101Christopher BrightlingNRES Committee East Midlands -- Leicester, The Old Chapel Royal Standard Place, Nottingham, UK1221301William MacNeeNRES Committee East Midlands -- Leicester, The Old Chapel Royal Standard Place, Nottingham, UK1221201David LomasNRES Committee East Midlands -- Leicester, The Old Chapel Royal Standard Place, Nottingham, UK1176001David SinghNRES Committee East Midlands -- Leicester, The Old Chapel Royal Standard Place, Nottingham, UK1129701Piotr KunaKomisja Bioetyki Uniwersytetu Medycznego, w Łodzi, Al. Kościuszki 4, Łódź, Poland1083301Ewa JassemKomisja Bioetyki Uniwersytetu Medycznego, w Łodzi, Al. Kościuszki 4, Łódź, Poland1285701Grazyna PulkaKomisja Bioetyki Uniwersytetu Medycznego, w Łodzi, Al. Kościuszki 4, Łódź, Poland1078601Jan KusKomisja Bioetyki Uniwersytetu Medycznego, w Łodzi, Al. Kościuszki 4, Łódź, Poland1229201Pawel GorskiKomisja Bioetyki Uniwersytetu Medycznego, w Łodzi, Al. Kościuszki 4, Łódź, Poland1215001Pere Casan ClaraComité Ético de Investigación Clínica de\
Asturias, Comité Ético de Investigación, ClínicaCelestino Villamil s/nEdificio Centro, de Rehabilitación- 5ª planta, Oviedo, Spain1215201Ferran Barbe IllaEC Hospital de Lleida Arnau de Vilanova, Comité Étcio de Investigación ClínicaAvda., Alcalde Rovira Roure 80Att. Montse, Solamilla, Lérida, Spain1284901David Ramos BarbonHospital de la Santa Creu e Sant Pau CEIC, Comité Ético de Investigación ClínicaSan\
Antoni Mª Claret 167-Pabellón 19Servicio de\
Farmacología Clínica Att.Marcela Domínguez\
Barcelona, Spain1291501Jose Luis Velasco GarridoHospital Universitario Virgen de la Victoria\
Comité Ético de Investigación ClínicaCampus\
Universitario Teatinos s/nUnidad de Calidad\
Málaga, Spain\
Comité Autonómico de Ensayos Clínicos de\
Andalucía CAEC\
Comité Ético de Investigación ClínicaAvda.de\
la Innovación s/n, Edificio Arena 1Secretaría\
del CEIC-Consejería de Salud/Sevilla, Spain1288401Krishna PudiSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1288501James StocksUni of TX Health Sciences Center, Center for Clinical Research 11937 US, Highway 271, Tyler, Texas, USA1288601David FuentesSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1270301Reynold PanettieriSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1196401Ritsu KunoSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1290001Gerard CrinerSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road\
Cincinnati, Ohio, USA1297001Wesley BraySchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1136201Nicholas NayakSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1297201Chaim BernsteinSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA1302301Michelle ZeidlerVA Medical Center, 16111 Plummer Street, Sepulveda, California, USA1196901Clinton CorderSchulman Associates Institutional Review\
Board, 4290 Glendale - Milford Road, Cincinnati, Ohio, USA[^1] Table S2List of primers used in the studyPrimer/probeTarget organism\
(gene)SequenceReferenceSourceS.pneumF*Streptococcus pneumoniae*\
*(Pneumolysin)*5ʹ-AGC GAT AGC TTT CTC CAA GTG G-3'Greiner et al,[@CIT0011] 2001IDTS.pneumR*Streptococcus pneumoniae*\
*(Pneumolysin)*5ʹ-CTT AGC CAA CAA ATC GTT TAC CG-3'Greiner et al,[@CIT0011] 2001IDTS.pneum\
probe*Streptococcus pneumoniae*\
*(Pneumolysin)*5ʹ-5CY5-ACC CCA GCA ATT CAA GTG TTC GCG-3BHQ2-3'Greiner et al,[@CIT0011] 2001IDTM.catF*Moraxella catarrhalis (outer membrane protein CopB)*5ʹ-GTG AGT GCC GCT TTA CAA CC-3'Greiner et al,[@CIT0012] 2003IDTM.catR*Moraxella catarrhalis (outer membrane protein CopB)*5ʹ-TGT ATC GCC TGC CAA GAC AA-3'Greiner et al,[@CIT0012] 2003IDTM.cat\
probe*Moraxella catarrhalis (outer membrane protein CopB)*5ʹ-6FAM-TGC TTT TGC AGC TGT TAG CCA GCC TAA-MGBNFQ-3'Greiner et al,[@CIT0012] 2003Applied Biosystems\
Life TechnologiesH.inflF*Haemophilus influenzae*\
*(fucP)*5ʹ-GCC GCT TCT GAG GCT GG-3'Price et al,[@CIT0013] 2015Eurofins\
GenomicsH.inflR*Haemophilus influenzae*\
*(fucP)*5ʹ-AAC GAC ATT ACC AAT CCG ATG G-3'Price et al,[@CIT0013] 2015Eurofins\
GenomicsH.infl\
probe*Haemophilus influenzae*\
*(fucP)*5ʹ-6FAM-TCC ATT ACT GTT TGA AAT AC-MGBNFQ-3'Price et al,[@CIT0013] 2015Applied Biosystems\
Life TechnologiesM. Nad16sFTotal bacteria (16S rDNA)5ʹ-ACT CCT ACG GGN GGC NGC A-3'Nadkarni et al,[@CIT0014] 2002IDTM. Nas16sRTotal bacteria (16S rDNA)5ʹ-GGA CTA CCA GGG TAT CTA ATC CTG TT-3'Nadkarni et al,[@CIT0014] 2002IDTM. Nad16s probeTotal bacteria (16S rDNA)5ʹ-56-FAM- CGT ATT ACC GCG GCT GCT GGC AC-36-TAMSp-3'Nadkarni et al,[@CIT0014] 2002IDT[^2] Table S3Clinical characteristics of COPD patientsParametersBenralizumab\
N=14Placebo\
N=15*P*-valueSex (male), n10120.682Age, years64 (10)65 (6)0.782Smoking history, pack-years46 (23)47 (22)0.899BMI, kg/m^2^28 (5)28 (5)0.978Exacerbations in last year0.64 (0.73)0.44 (0.47)0.3956MWD, metres466 (135)336 (122)0.011BODE index2 (2)3 (3)0.634SGRQ total43 (20)44 (18)0.940SGRQ symptoms63 (22)57 (24)0.482SGRQ activity54 (28)50 (24)0.674SGRQ impacts30 (21)35 (18)0.443VAS dyspnea33 (30)39 (29)0.583VAS cough34 (27)37 (26)0.829VAS sputum35 (20)38 (28)0.765VAS purulence27 (31)13 (18)0.1520Pre-bronchodilator FEV~1,~ L1.26 (0.52)1.50 (0.55)0.249Post bronchodilator FEV~1,~ L1.37 (0.56)1.59 (0.53)0.299FEV~1~% predicted46 (15)50 (17)0.147FEV~1~/FVC ratio47 (9)50 (10)0.403RV, L3.93 (1.32)3.51 (1.30)0.407TLC, L7.30 (2.03)6.50 (2.21)0.331DLCO, %80.2 (26.2)88.2 (24.1)0.409Blood eosinophils/μL230 (190)210 (140)0.789Sputum eosinophil, %^a^5.1 (2.4, 5.9)4.1 (0.9, 19.3)0.991[^3]
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[^1]: **Abbreviations:** IEC, independent ethics committee; IRB, institutional review board; UK, United Kingdom; USA, United States of America.

[^2]: **Abbreviations:** H.infl, *Haemophilus influenzae*; IDT, Integrated DNA Technologies; M.cat, *Moraxella catarrhalis*; rDNA, recombinant deoxyribonucleic acid; S.pneum, *Streptococcus pneumoniae.*

[^3]: **Notes:** Data are presented as mean (SD) unless otherwise stated. ^a^Median (interquartile range).

    **Abbreviations:** BMI, body mass index; BODE, body mass index airflow obstruction, dyspnoea, and exercise; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; SD, standard deviation; SGRQ, St. George's respiratory questionnaire; TLC, total lung capacity; VAS, visual analog scale; 6MWD, 6-min walk distance.
